Akerlund M, Melin P, Maggi M
Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.
Adv Exp Med Biol. 1995;395:595-600.
In order to study the involvement of oxytocin (OT) and vasopressin (AVP) in mechanisms of uterine activation and to clarify the therapeutic potential of antagonists to these hormones in preterm labour and primary dysmenorrhoea, studies of human uterine contractility in vivo and in vitro as well as measurements of OT and AVP V1a receptors were performed. Good correlations between OT receptor concentrations and effects on contractility were observed in both the pregnant and non-pregnant states, which indicates that OT acts specifically on its own receptor in the uterus. For AVP there was lack of such correlation which may suggest that this hormone influences both the OT and AVP V1a receptor sites. At the onset of labour both preterm and at term no marked increase in the OT receptor concentration was observed, but OT may still be involved in the initiation of labour, being produced locally in the uterus and not detectable in plasma. We observed a reduced OT receptor concentration in advanced labour and after OT infusion, which suggests that OT influences its own receptor. The AVP V1a receptor concentration and the effect of AVP on the uterus were about equal to those for OT, and the concentration of AVP V1a receptors also tended to decrease in advanced labour, observations which support an involvement also of AVP in the mechanisms of labour. In non-pregnant women AVP receptors as well as uterine effects of AVP in vitro and in vivo were about five times higher than those for OT, and the effect of AVP was increased premenstrually. This firmly supports an aetiological role of this peptide in the uterine hyperactivity of primary dysmenorrhoea. We have also shown that the analogue 1-deamino-2-D-Tyr-(OEt)-4-Thr-8-Orn-OT, which blocks both the OT and AVP V1a receptor sites, given by intravenous infusion inhibits both preterm labour and dysmenorrhoea, and this is in agreement with our receptor and contractility findings.
为了研究催产素(OT)和血管加压素(AVP)在子宫激活机制中的作用,并阐明这些激素的拮抗剂在早产和原发性痛经中的治疗潜力,我们进行了体内和体外人体子宫收缩性研究以及OT和AVP V1a受体的测量。在妊娠和非妊娠状态下,均观察到OT受体浓度与对收缩性的影响之间存在良好的相关性,这表明OT在子宫中特异性作用于其自身受体。对于AVP,缺乏这种相关性,这可能表明该激素影响OT和AVP V1a受体位点。在早产和足月分娩开始时,未观察到OT受体浓度有明显增加,但OT仍可能参与分娩的启动,它在子宫局部产生且在血浆中无法检测到。我们观察到在分娩后期和OT输注后OT受体浓度降低,这表明OT影响其自身受体。AVP V1a受体浓度以及AVP对子宫的作用与OT的大致相等,并且在分娩后期AVP V1a受体浓度也趋于降低,这些观察结果支持AVP也参与分娩机制。在非妊娠女性中,AVP受体以及AVP在体外和体内对子宫的作用比OT高约五倍,并且AVP的作用在月经前增加。这有力地支持了这种肽在原发性痛经子宫活动亢进中的病因学作用。我们还表明,静脉输注的同时阻断OT和AVP V1a受体位点的类似物1-脱氨基-2-D-酪氨酸-(OEt)-4-苏氨酸-8-鸟氨酸-OT可抑制早产和痛经,这与我们的受体和收缩性研究结果一致。